How effective is natalizumab as second-line treatment for multiple sclerosis in daily clinical praxis?
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
How effective is natalizumab as second-line treatment for multiple sclerosis in daily clinical praxis? / Sørensen, Per Soelberg.
I: European Journal of Neurology, Bind 16, Nr. 3, 2009, s. 287-288.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
Sørensen, PS 2009, 'How effective is natalizumab as second-line treatment for multiple sclerosis in daily clinical praxis?', European Journal of Neurology, bind 16, nr. 3, s. 287-288.
APA
Sørensen, P. S. (2009). How effective is natalizumab as second-line treatment for multiple sclerosis in daily clinical praxis? European Journal of Neurology, 16(3), 287-288.
Vancouver
Sørensen PS. How effective is natalizumab as second-line treatment for multiple sclerosis in daily clinical praxis? European Journal of Neurology. 2009;16(3):287-288.
Author
Bibtex
@article{83538d405c0f11df928f000ea68e967b,
title = "How effective is natalizumab as second-line treatment for multiple sclerosis in daily clinical praxis?",
abstract = "Udgivelsesdato: 2009/3",
author = "S{\o}rensen, {Per Soelberg}",
year = "2009",
language = "English",
volume = "16",
pages = "287--288",
journal = "European Journal of Neurology",
issn = "1351-5101",
publisher = "Wiley-Blackwell",
number = "3",
}
RIS
TY - JOUR
T1 - How effective is natalizumab as second-line treatment for multiple sclerosis in daily clinical praxis?
AU - Sørensen, Per Soelberg
PY - 2009
Y1 - 2009
N2 - Udgivelsesdato: 2009/3
AB - Udgivelsesdato: 2009/3
M3 - Journal article
VL - 16
SP - 287
EP - 288
JO - European Journal of Neurology
JF - European Journal of Neurology
SN - 1351-5101
IS - 3
ER -
ID: 19662984